e-Article
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
Document Type
Article
Author
Source
In ESMO Open May 2024 9(5)
Subject
Language
ISSN
2059-7029